Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers

Mohamed E. Ahmed, Tilman Todenhöfer, R. Jeffrey Karnes, Roland Seiler

Research output: Contribution to journalReview articlepeer-review


Prostate cancer and bladder cancer are two of the most common urologic cancers. Cancer risk stratification and prediction of prognosis have always been challenging. Following recent advances in genomic and proteomic technologies, several genomic biomarkers have been developed and proposed as a noninvasive and nonexpansive approach that can supplement our current data to improve prediction and accuracy. Several biomarkers have shown efficacy in patient risk stratification and in predicting prognosis. Here we provide a mini-review of current RNA biomarkers approved by the US Food and Drug Administration, including the Decipher, Oncotype DX Prostate, and Prolaris tests. We also provide a summary of their approved clinical utility in prostate cancer and bladder cancer management. Patient summary: A number of tests are available for measuring expression levels of genes related to prostate or bladder cancer. We review the usefulness of these tests in stratifying risk for patients and predicting their prognosis.

Original languageEnglish (US)
Pages (from-to)663-666
Number of pages4
JournalEuropean Urology Focus
Issue number3
StatePublished - May 2022


  • Biomarkers
  • Bladder cancer
  • Decipher
  • Oncotype DX
  • Prolaris
  • Prostate cancer
  • RNA biomarkers

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers'. Together they form a unique fingerprint.

Cite this